Daewoong Pharmaceutical (South Korea)

Daewoong Pharmaceutical (South Korea)

Daewoong Pharmaceutical Co., Ltd. is a pharmaceutical company headquartered in Seoul, South Korea. Daewoong Pharmaceutical primarily engages in the manufacture of pharmaceutical products, including prescription and over-the-counter healthcare products. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Daewoong Pharmaceutical (South Korea), South Korea, covering academic research published from 2000 to 2024. Read More.


Open Access Percentage

52%


Total
Publications

322


Total Open
Publications

168


Total
Citations

6.6K


Open Access
Percentage

52%


Total
Publications

322


Total Open
Publications

168


Total
Citations

6.6K

Wikipedia

Website

download

Breakdown

18% 29% 5% 48%

Publisher Open

18%

Both

29%

Other Platform Open

5%

Closed

48%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

0510152025303540Total Publications
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

47%OA Journal

OA Journal 47%

72

Hybrid 25%

38

No Guarantees 28%

42

Other Platform Open

Domain 89%

97

Public 22%

24

Preprint 11%

12

Other Internet 8%

9

Institution 7%

8

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
96
Europe PMC
Domain
36
Semantic Scholar
Public
21
Research Square
Preprint
6
DOI
Other Internet
6
Yonsei University Medical Library - YUHSpace
Institution
3
Taylor and Francis Group - Dove Medical Press
Other Internet
3
Seoul National University - Seoul National University Open Repository
Institution
3
MDPI
Preprint
3
SRCE - University of Zagreb University Computing Centre - HRČAK - Portal of Croatian Scientific and Professional Journals
Institution
2
1 / 2

Data updated 7 April 2025

Share

Share

Share